| Aggregate evidence quality: B; randomized controlled trials with limitations. . | |
|---|---|
| Benefit | Increase clinical cures with narrowest spectrum drug; stepwise increase in broadening spectrum as risk factors for resistance increase. |
| Harm | Adverse effects of antibiotics including development of hypersensitivity. |
| Cost | Direct cost of antibiotic therapy. |
| Benefits-harm assessment | Preponderance of benefit. |
| Value judgments | Concerns for not encouraging resistance if possible. |
| Role of patient preference | Potential for shared decision-making that should incorporate the caregiver’s experiences and values. |
| Intentional vagueness | None. |
| Exclusions | May include allergy or intolerance. |
| Strength | Recommendation. |
| Aggregate evidence quality: B; randomized controlled trials with limitations. . | |
|---|---|
| Benefit | Increase clinical cures with narrowest spectrum drug; stepwise increase in broadening spectrum as risk factors for resistance increase. |
| Harm | Adverse effects of antibiotics including development of hypersensitivity. |
| Cost | Direct cost of antibiotic therapy. |
| Benefits-harm assessment | Preponderance of benefit. |
| Value judgments | Concerns for not encouraging resistance if possible. |
| Role of patient preference | Potential for shared decision-making that should incorporate the caregiver’s experiences and values. |
| Intentional vagueness | None. |
| Exclusions | May include allergy or intolerance. |
| Strength | Recommendation. |